Method for preparation and application of autological erythrocytes from umbilical blood for anemia correction in newborns

FIELD: medicine.

SUBSTANCE: method includes the following steps: umbilical cord samples collection, processing, placement for storage and rejection of samples, a pre-transfusion processing for umbilical blood samples. At the pretransfusion preparation stage, the erythrocyte mass from the plasma is separated by centrifugation at acceleration of 3768 g for 15 minutes at a temperature of +4°C. Then the auto-erythromass samples pass the procedure of auto-erythrocytes washing from the preservative and hemolyzed cells formed during umbilical cord sample storage. To do this, 100 ml of sterile physiological sodium chloride solution is added to the packet with auto-erythromass in the umbilical erythromass and physiological solution ratio of 1:1 and centrifuged at 1971 g acceleration for 10 minutes at a temperature of +4°. After this, the supernatant is removed using a plasma extractor. The washed umbilical erythrocytes are filtered through a microaggregate filter. All samples of autologous erythrocytes of umbilical blood pass quality control: the degree of hemolysis and quantitative indicators of blood cells, hemoglobin and hematocrit are determined.

EFFECT: invention allows to correct anemia in newborns by a single blood transfusion, without occurrence of posttransfusion complications associated with donor blood components transfusion.

11 tbl, 3 ex



Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to field of biotechnology, namely to obtaining conjugates of glycoprotein, possessing erythropoietin activity, with polyethylenepiperazine N-oxide derivatives, and can be used in medicine. Conjugate of erythropoietin, corresponding to general formula (1): [-Ak-Bl-Cm-(D-C(O)-NH-EPO)p-]n, with molecular weight 50-190 kDa is obtained.

EFFECT: invention makes it possible to obtain stable conjugate of erythropoietin, containing biodegradable fragments of poly-1,4-ethylenepiperazine N-oxides, which makes it possible to increase medication safety due to sharp reduction of antigenicity (immunogenicity), toxicity and, therefore, probability of side effects, reduction of frequency of injections and regimen of dosing, as well as provides possibility of carrying out synthesis in water solutions, increase manufacturability, economical efficiency and ecological safety of production.

16 cl, 2 tbl, 9 ex

Crystals // 2556206

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes crystals of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulphonyl)acetamide ("compound A"), as a form I of the compound A crystal, which shows diffraction peaks at 9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees in its power X-ray diffraction spectrum, as a form II of the compound A crystal, which shows diffraction peaks at 9.0 degrees, 12.9 degrees, 20.7 degrees and 22.6 degrees in its power X-ray diffraction spectrum, as a form III of the compound A crystal, which shows diffraction peaks at 9.3 degrees, 9.7 degrees, 16.8 degrees, 20.6 degrees and 23.5 degrees in its power X-ray diffraction spectrum. There are also described methods for producing the forms I, II and III of the compound A crystal, based pharmaceutical composition and PGI2 receptor agonist agent, an accelerating agent for angiogenic therapy, gene engineering or autoimmune bone marrow transplantation, and an accelerating agent for angiogenesis for peripheral artery recovery or angiogenic therapy on the basis thereof; there are also described a preventive or therapeutic agent for a wide range of diseases and conditions.

EFFECT: preparing the new therapeutic agent for the wide range of diseases and conditions.

11 cl, 6 dwg, 6 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: what is involved is an integrated pathogenetic therapy containing detralex 3 tablets two times a day (a daily dose of diosmin 2,700 mg, hesperidin 300 mg) for 4 days, then 2 tablets two times a day (a daily dose of diosmin 1,800 mg, hesperidin 200 mg) for 9 days, Trombovazim 1 tablet (800 units) 2 times a day for 15 days as a basic course, then 1 tablet (800 units) 1 time a day) 15 days as a supporting course, and a preparation of thioctic acid 600 mg intravenously in normal saline 200.0 drop-by-drop at max. 60 drops/min for 13 days, then 600 mg a day in the form of tablets for 17 days.

EFFECT: effective reduction of reperfusion syndrome in the given category of patients by increasing venous vascular tone, improving rheological blood properties and trophism of injured nerve terminals.

2 cl, 10 dwg, 9 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically to pharmacology, and concerts agents having an effect on the rheological properties of blood. What is presented is using the chemical modification product of hydroxyethylated starch O-(2-hydroxyethyl)-(1,4)-α-D-glucan, the hybrid macromolecular compound O-(4-hydroxy-3,5-di(1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)benzyl)oxy)ethyl)-O-(2-hydroxyethyl)-(1,4)-α-D-glucan as an agent improving the rheological properties of blood. The invention can be used in a complex therapy of pathologies accompanied by blood hyperviscosity.

EFFECT: limiting an increase in blood viscosity.

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a group of inventions concerning a new application of bicyclo[2,2,2]octane-2-carboxylic acid salt. What is presented is using it for treating dysphoria in a person suffering epilepsy for treating alcohol addiction, for reducing the level of hepatic function marker specified in AST (aspartate aminotransferase), ALT (alanine aminotransferase) or bilirubin in the person for reducing an erythrocyte sedimentation rate, as well as for reducing a number or an intensity of epileptic attacks in a daily dose of min 400 mg.

EFFECT: implementing the above applications with no negative effect on patient's behaviour and the functions of the main organs and systems.

19 cl, 6 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: pentoxifylline is intravenously administered in a daily dose of 5 mg/kg of newborn's body weight for the first three days of life.

EFFECT: method enables providing the considerably higher clinical effectiveness, causes no severe complications; it is accessible and efficient.

1 ex, 5 tbl

FIELD: medicine.

SUBSTANCE: invention can be applicable for treating patients suffering haemorrhagic shock. Namely, the invention refers to a hyperoxygenated agent for venous oxygen saturation, which represents an aqueous solution containing sodium chloride 0.85%, sodium hydroxycarbonate 0.10% and hydrogen peroxide 0.05-0.29%.

EFFECT: higher safety and effectiveness by blood oxygen saturation, stable osmotic activity, higher alkalinity and buffer capacity.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to substituted isoquinolines and isoquinolinones of formula (I) and to their stereoisomer and/or tautomer forms and/or pharmaceutically acceptable salts, wherein R1 is H, OH or NH2; R3 is H; R4 is H, halogen or (C1-C6)alkylene-R'; R5 is H, halogen, (C1-C6)alkyl; R7 is H, halogen, (C1-C6)alkyl, O-(C1-C6)alkyl; R8 is H; R6 is absent; or is one of (C1-C4)alkylene related to a cycloalkyl ring related to a cycloalkyl ring, wherein (C1-C4)alkylene forms a second bond to another carbon atom of the cycloalkyl ring to form a bicyclic ring system, R10 is H, phenyl, or pyridine, wherein phenyl is unsubstituted or substituted; R11 is H, (C1-C6)alkyl; or R11 and R12 together with the carbon atom to which they are attached form (C3)cycloalkyl; R12 is (C1-C6)alkyl, (C3-C8)cycloalkyl or phenyl; or R12 is H, provided r=2 and another R12 is other than H; or R11 and R12 together with the carbon atom to which they are attached form (C3)cycloalkyl; R13 and R14 are independently H, (C1-C6)alkyl, (C1-C6)alkylene-R', C(O)O-(C1-C6)alkyl, n is equal to 0; m is equal to 1 or 2; s is equal to 1 or 2; r is equal to 1 or 2; L is O, NH; R' is (C3-C8)cycloalkyl, (C6-C10)aryl; wherein in R11 and R12 residues, alkyl is unsubstituted or optionally substituted by one OCH3; wherein in R11 and R12 residues, alkyl is unsubstituted or optionally substituted by one or more halogens; wherein in R10 and R12 residues, (C6-C10)aryl is unsubstituted or optionally substituted by one or two groups optionally specified in halogen, CN, (C1-C6)alkyl, O-(C1-C6)alkyl, SO2-(C1-C6)alkyl, CF3 and OCF3. Also, the invention refers to using a compound of formula (I).

EFFECT: there are prepared new isoquinoline and isoquinolinone derivatives effective in treating and preventing the diseases related to Rho-kinase inhibition.

38 cl, 132 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gastroenterology and infectious diseases, and concerns the prevention of developing thrombocytopenia in the patients suffering chronic hepatitis C (CHC) in a combination with Helicobacter pylori infection and receiving a combined antiviral therapy (CAVT). For this purpose, the beginning of the CAVT is preceded by a 10-14-day eradication therapy according to the schedule: a proton pump inhibitor in a standard dose twice a day + amoxicillin 500 mg 4 times a day or 1000 mg twice a day + clarithromycin 500 mg twice a day. The CAVT starts 2 weeks after the completion of the eradication therapy.

EFFECT: method provides reducing a risk of developing or progressing thrombocytopenia in the patients with chronic hepatitis C with underlying CAVT.

4 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: perftoran is administered intravenously at 5-20 ml per 1 kg of body weight.

EFFECT: reducing side effects in treating methemoglobinemia by the property of perftoran to transform methemoglobin into oxyhemoglobin.

6 dwg, 2 tbl

FIELD: veterinary medicine.

SUBSTANCE: method comprises subcutaneous administration of antibiotic preparation enroxyl 5% at a dose of 0.1 ml/kg daily one time a day for 7 days and intramuscular administration of homeopathic preparation ovarinin at a dose of 1 ml/kg one time for 4 days, 4-fold.

EFFECT: use of the invention enables to increase the efficiency of treatment, to reduce treatment time and to restore reproductive function of dogs.

2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new (R)-stereoisomers of substituted 2-thioxo-imidazolidin-4-ones of formula 1 or to spiroanalogues thereof, which possess the properties of an androgen receptor agonist, to versions of a method for producing them, and to intermediate compounds 2.1-2.4 for producing compounds of formula 1. The invention also refers to a pharmaceutical composition presented in the form of tablets, capsules, injections. In formula 1 R1 represents OH, NH2, or OR4 group; R2 and R3 represent methyl, or R2 and R3 represent CH2-CH2 group; R4 represent C1-C4alkyl or cyclopropyl. The compounds 2.1-2.4 are described by structural formulas:

EFFECT: compounds of formula 1 can be used for producing the medicinal product applicable for treating a cancer disease, such as prostate cancer, breast cancer.

17 cl, 1 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to a method of treatment or prevention of epilepsy. For this purpose recombinant human interleukin-2 is introduced to the patient with a reduced BDNF concentration in blood serum and/or plasma. The group of inventions also relates to the application of interleukin-2 for the treatment or prevention of the said disease.

EFFECT: application of the claimed group of inventions makes it possible to apply recombinant interleukin-2 as a single therapeutic agent in the treatment of pharmacoresistant epilepsy, associated with the insufficient BDNF production.

8 cl, 5 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: what is presented is using meso-tetra(3-pyridyl)bacteriochlorin of structural formula (I) as a near-infrared photosensitiser for a photodynamic therapy. Doses 1.0-2.5 mg/kg of the declared photosensitiser have provided 70-100% tumour growth inhibition, 80-131% increase in life expectancy and 25-100% animals' recovery by selective tumour collection and fast clearance.

EFFECT: high photoinduced activity on human tumour cells of various epithelial origin and high dose-dependent anti-tumour effectiveness in the animal with tumours of various origins.

5 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: cryoprotector is opened in a laminar flow unit; a special syringe of asyringe pump is filled with a cryoprotector; that is followed by introducing a filter solution of the cryoprotector - 55% dimethylsulphoxide with 5% dextran 40 at temperature +4°C in a nucleated cell suspension with haemopoietic stem cells in a cryopackage with the concentrate and mixing mechanically in a mixing apparatus, transferring the system together with the cryoprotector flask into the laminar flow unit; the air is released from the cryopackage and portion of the suspension; the package is sealed and placed into a shrink bag; that is followed by programmed multi-stage freezing, the first stage of which keeping the mixture of the suspension with the stem cells and cryoprotector - a freezing sample - for 10 min at temperature +4°C; the second stage is cooled at a rate of 1°C/min to temperature -12°C; the thirst stage provides cooling at a rate of 20°C/min to temperature -60°C; at the fourth stage, the sample is heated at a rate of 10°C/min to temperature -18°C; at the fifth stage, the sample is cooled at a rate of 1°C/min to -60°C; at the end of the freezing program, the sample is cooled at a rate of 3°C/min to temperature -100°C; after freezing, the sample is placed into a quarantine dewar with liquid nitrogen until infection and bacteriological fungal contamination test results are obtained. After termination of the quarantine shelf life, the sample with haemopoietic stem cells are placed for long-term storage at temperature not exceeding -150°C, into the dewar with liquid nitrogen if observing negative test results. If the infection and bacterial and/or fungal contamination test results are positive, the sample with haemopoietic stem cells are transferred into the dewar with liquid nitrogen for infectious material for long-term storage.

EFFECT: invention enables increasing cell viability in the sample.

3 cl, 4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to oncourology, and can be used in the non-surgical treatment of the patients suffering early stages of prostate malignant tumour. A method of treating prostate cancer with using prolonged prodrug of octreotide accompanying surgical or drug-induced castration involves a) measuring pre-therapeutic prostate-specific antigen; b) measuring pre-therapeutic blood plasma chromogranin A; c) selecting the patients having high blood chromogranin A of more than 3 nmol/l; d) conducting a therapy with prolonged prodrug of octreotide in a combination with dexamethasone in the selected patients; e) controlling the prostate-specific antigen variation every month and monitoring a decrease thereof in the patients by measuring it intra-therapeutically according to the stage d); the therapeutic efficacy according to the stage d) is evaluated by a therapeutic response, which is accompanied by maximum decrease of the prostate-specific antigen.

EFFECT: invention enables providing the higher therapeutic efficacy in the patients suffering prostate cancer at the different stages.

3 cl, 1 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to balneology. A balneological agent for treating and preventing various diseases is prepared by the gradual and sequential mixing at room temperature of yellow clay, natural brine of Bolshoy Tambukan Lake, sage essence, dimethyl sulphoxide in certain relations.

EFFECT: agent possesses the more prominent therapeutic effect.

5 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: tissue-specific matrix is obtained by performing a perfusion washing and a decellularisation of a parenchymal organ. Herewith 60-120 minutes before the perfusion washing of the donor organ, measures to prevent intravascular blood cell aggregation and microcirculation disturbances are taken and involve the intramuscular or intravenous administration of a disaggregant or disaggregants (heparin and trental) into a donor. That is followed by an organ perfusion by administering into its vascular bed phosphate-buffered normal saline of the following composition: 138 mM NaCl, 2.67 mM KCl, 1.47 mM KH2PO4, 8.1 mM Na2HPO4, distilled water up to 1l and containing 1% serum albumin and 10-15% glycerol or 10-15% dimethyl sulphoxide with pH 7.4 in an amount equal to a double amount of the vascular bed of the organ at a perfusion pressure of 100-120 mm Hg in its arterial system. Thereafter, the decellularised organ is ground to a particle size of 0.5mm to 4mm; the ground fragments are portioned in an amount of 5-10g, and each portion is frozen by immersing into liquid nitrogen gas for 5-10 minutes. The frozen portions are re-ground to a particle size of no more than 600 mcm; then each portion is de-frozen by re-suspending in phosphate-buffered normal saline 30-70ml of the following composition containing 138 mM NaCl, 2.67 mM KCl, 1.47 mM KH2PO4, 8.1 mM Na2HPO4, distilled water up to 1l , with pH 7.4, at a room temperature. The prepared suspension is cleaned from the particles of less than 200mcm; the prepared fraction is lyophilised and sterilised to prepare the target matrix samples.

EFFECT: using the invention enables providing the more complete decellularisation procedure ensured by preventing the disturbed microcirculation in the donor organ, providing higher density and uniformity of the re-cellularisation of the entire matrix and easier control thereof by increasing the matrix adhesive surface areas for the contact to inoculating cells as prepared in the form of powder.

4 cl, 5 ex, 9 dwg

FIELD: biotechnologies.

SUBSTANCE: invention relates to new heterogeneous ring compounds containing a pentatomic rings, condensed with other nuclei, only with one atom of oxygen as a heteroatom, namely to derivants of acetamid N-((1S)-1',2',3'-trimethoxy-6,7-dihydro-1H-benzo[5',6':5,4]cyclohepta-[3,2-f]benzofuran-1-il) with the general formula 1 , where R - substituent, R=Ph, pyridine-2-il, CH2OH, CH(CH3)OH, CH2CH2OH, CH2OAc, (CH2)8CO2Me or CH2N(CH2CH3)2, and also to their application as an active component of antitumoral medicinal preparation.

EFFECT: increase of activity with inhibition of proliferation of the tumour cells.

10 cl, 3 dwg, 8 ex

FIELD: chemistry.

SUBSTANCE: set task is solved by application of final slag, formed in production of ferrovanadium by alumino-silicothermic method as bactericidal material.

EFFECT: extension of raw material resources for bactericidal materials.

1 tbl

FIELD: medicine.

SUBSTANCE: method for preparing a haematogenous powder from a blood clot involves blood sampling from animals or humans, setting-out and centrifugation of the blood with forming of blood serum and blood clot; the blood serum is poured off, and the blood clot is poured into a vessel and added with ethanol and incubated; the blood clot is then separated, dried and powdered under certain conditions.

EFFECT: method enables preparing the haematogenous powder from the blood clot containing all primary blood components.